A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
about
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
P2860
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A phase I trial of ganetespib ...... itive metastatic breast cancer
@en
type
label
A phase I trial of ganetespib ...... itive metastatic breast cancer
@en
prefLabel
A phase I trial of ganetespib ...... itive metastatic breast cancer
@en
P2093
P2860
P50
P1476
A phase I trial of ganetespib ...... itive metastatic breast cancer
@en
P2093
Clifford Hudis
David Solit
Eleonora Teplinsky
Gabriella D'Andrea
James Speyer
Karen Cadoo
Kent Friedman
Komal Jhaveri
Sarat Chandarlapaty
P2860
P2888
P356
10.1186/S13058-017-0879-5
P577
2017-08-02T00:00:00Z
P6179
1090945820